Dermaliq Therapeutics
Gordon Dow, PharmD (Chairman of the SAB) is former CEO, Founder & CTO of Dow Pharmaceutical Sciences Inc, a dermatology specialty company which developed topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies. Dow was acquired by Valeant, now Bausch Health, for US$ 400 million in 2008. Dr. Dow is a recognized expert in topical product formulations and a leading innovator for a number of approved and successful dermatology products.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Dermaliq Therapeutics
Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients